



# Market Announcement

25 September 2018

---

## MGC Pharmaceuticals Limited (ASX: MXC) – Suspension from Official Quotation

### Description

The securities of MGC Pharmaceuticals Limited ('MXC') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MXC, pending the release of an announcement regarding a material commercial transaction with a Canadian cannabis company.

### Issued by

**Anjuli Sinniah**

Senior Adviser, Listings Compliance (Perth)

25 September 2018

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Sir/Madam

**MGC Pharmaceuticals Ltd – Voluntary Suspension Request**

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests a voluntary suspension over the Company’s securities from the commencement of trade on Tuesday, 25th September 2018.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the request:

1. The reason for the request of the voluntary suspension is to allow the ASX to complete its review of the terms in respect of a material commercial transaction with a Canadian cannabis company for MGC Derma.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Thursday, 27th September 2018, when it anticipates it will be in a position to make an announcement to the market in respect of the abovementioned matter.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

*[signed electronically without signature]*

Kate Sainty

**Joint Company Secretary**

**MGC Pharmaceuticals Ltd**